Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Patients with Advanced Prostate Cancer Can Benefit From Individual Radiation Therapy

Summary by Deutsches Ärzteblatt
Bad Homburg – Highly pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) could benefit from individualised radioligand therapy, in which a form of the isotope Lutetium-177 is inserted into the cancer cell via the prostate-specific membrane antigen (PSMA).
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

Deutsches ÄrzteblattDeutsches Ärzteblatt

Patients with Advanced Prostate Cancer Can Benefit From Individual Radiation Therapy

Bad Homburg – Highly pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) could benefit from individualised radioligand therapy, in which a form of the isotope Lutetium-177 is inserted into the cancer cell via the prostate-specific membrane antigen (PSMA).

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Deutsches Ärzteblatt broke the news on Monday, August 31, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Bad Homburg icon

Bad Homburg

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal